Ensysce Biosciences (NASDAQ: ENSC)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-15 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.060 | ||||||
REV | 603.098K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Ensysce Biosciences (NASDAQ: ENSC) through any online brokerage.
Other companies in Ensysce Biosciences’s space includes: Vincerx Pharma (NASDAQ:VINC), Aeglea BioTherapeutics (NASDAQ:AGLE), Cabaletta Bio (NASDAQ:CABA), Monopar Therapeutics (NASDAQ:MNPR) and Brooklyn (NASDAQ:BTX).
The latest price target for Ensysce Biosciences (NASDAQ: ENSC) was reported by Lake Street on Tuesday, November 30, 2021. The analyst firm set a price target for 4.00 expecting ENSC to rise to within 12 months (a possible 602.99% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Ensysce Biosciences (NASDAQ: ENSC) is $0.569 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Ensysce Biosciences.
Ensysce Biosciences’s Q2 earnings are confirmed for Monday, August 15, 2022.
There is no upcoming split for Ensysce Biosciences.
Ensysce Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.